Regenxbio Profit Margin

Regenxbio (RGNX) currently reports a profit margin of -112.58% as of June 2026. That compares with -112.7% in the prior-year period — up 0.1% year over year. That is below the Healthcare sector average of 10.58%. Use the charts on this page to explore Regenxbio's profit margin history and peer comparisons.

Regenxbio's profit margin increased from -112.7% to -112.58% — a 0.1% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Regenxbio's profit margin of -112.58% is lower than the Healthcare sector average of 10.58%. That is roughly 1164.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Regenxbio's current -112.58% should be judged against Healthcare norms (sector average: 10.58%) and against RGNX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -112.58%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 10.58%. From there, open related valuation or income-statement pages for Regenxbio, and consider following RGNX for alerts when major investors trade the stock.